Entering text into the input field will update the search result below

OncoGenex cancer drug reduces risk of death in metastatic bladder cancer

Dec. 19, 2014 10:05 AM ETAchieve Life Sciences, Inc. (ACHV) StockBy: Douglas W. House, SA News Editor
  • OncoGenex Pharmaceuticals (OGXI -3.5%) announces the results of a Phase 2 study assessing the efficacy of low (600 mg) and high (1000 mg) dose apatorsen in combination with gemcitabine/cisplatin chemotherapy compared to chemotherapy alone in patients with metastatic bladder cancer.
  • The 600 mg dose showed a 14% reduction in risk of death and a 17% reduction in progressive disease compared to chemo alone. In a subgroup of patients with lower performance status (Karnofsky score <=80%), low dose apatorsen plus chemo reduced the risk of death 50%.
  • Less benefit was observed with the high dose due to a high incidence of adverse events and discontinuation of both apatorsen and chemo. The low dose was well tolerated.
  • The company will work with investigators and regulatory authorities to clarify a development path forward.

Recommended For You

More Trending News

About ACHV Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ACHV--
Achieve Life Sciences, Inc.